Last reviewed · How we verify

NCT04832828

Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive

Completed Last updated 6 April 2021
What this trial tests

trial testing Roth´s Test in Covid19 in 114 participants. Completed in 28 November 2020.

Timeline
1 June 2020
Primary endpoint
28 November 2020
28 November 2020

Quick facts

Lead sponsorUniversidad Autonoma de Madrid
StatusCompleted
Study typeOBSERVATIONAL
Enrollment114
Start date1 June 2020
Primary completion28 November 2020
Estimated completion28 November 2020
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Universidad Autonoma de Madrid — full company profile →

Who can join

Adults 12 to 99, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The presence of the described silent hypoxia in subjects diagnosed with COVID19 highlights the need for valid tools to assess respiratory capacity. The Roth test has been associated with acceptable sensitivity and specificity criteria in patients with previous respiratory pathology; however, its validity in this type of patient has not been proven.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Universidad Autonoma de Madrid trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04832828.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing